ARGENX SE-ADR (ARGX) Given Daily Coverage Optimism Score of 0.22

News headlines about ARGENX SE-ADR (NASDAQ:ARGX) have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ARGENX SE-ADR earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.7500307092075 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

ARGENX SE-ADR (ARGX) traded up 1.01% during mid-day trading on Monday, reaching $21.10. The company had a trading volume of 1,639 shares. ARGENX SE-ADR has a 12 month low of $17.33 and a 12 month high of $25.00. The stock’s market cap is $566.98 million. The firm’s 50-day moving average price is $20.74 and its 200-day moving average price is $20.72.

ARGX has been the subject of several recent analyst reports. JMP Securities initiated coverage on ARGENX SE-ADR in a research report on Monday, June 12th. They issued an “outperform” rating and a $33.00 target price for the company. Cowen and Company reissued a “buy” rating on shares of ARGENX SE-ADR in a research report on Thursday, August 24th. Finally, Wedbush reissued an “outperform” rating on shares of ARGENX SE-ADR in a research report on Monday, June 12th.

WARNING: This piece was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at

ARGENX SE-ADR Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Receive News & Ratings for ARGENX SE-ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARGENX SE-ADR and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply